Nanexa AB (publ)

Stockholm Stock Exchange NANEXA.ST

Nanexa AB (publ) Return on Assets (ROA) for the year ending December 31, 2023: -57.76%

Nanexa AB (publ) Return on Assets (ROA) is -57.76% for the year ending December 31, 2023, a -67.85% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Nanexa AB (publ) Return on Assets (ROA) for the year ending December 31, 2022 was -34.41%, a -57.73% change year over year.
Nanexa AB (publ) Return on Assets (ROA) for the year ending December 31, 2021 was -21.82%, a 46.11% change year over year.
Nanexa AB (publ) Return on Assets (ROA) for the year ending December 31, 2020 was -40.48%, a -10.78% change year over year.
Nanexa AB (publ) Return on Assets (ROA) for the year ending December 31, 2019 was -36.54%, a 8.72% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Stockholm Stock Exchange: NANEXA.ST

Nanexa AB (publ)

CEO	Mr. David Westberg
IPO Date	June 17, 2015
Location	Sweden
Headquarters	Virdings AllE 32B
Employees	19
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

Key trends

Past 5 years